4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients (ENTERPRISE)

Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients (ENTERPRISE)

Study Description
Brief Summary:
Alterations of acid-base equilibrium are very common in critically ill patients and understanding their pathophysiology can be important to improve clinical treatment.

Condition or disease Intervention/treatment
Sepsis Septic Shock Critical Illness Respiratory Acidosis Respiratory Alkalosis Acid-Base Imbalance Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma. Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood Diagnostic Test: Biomolecular analysis of plasma proteins.

Detailed Description:

Acid-base equilibrium has been object of study for more than 100 years in medicine because of its relevance in patients' management and in determining their prognosis, especially in the ICU.

A concept closely related to acid-base equilibrium is that of "buffer", term used to define any substance able to limit the changes in pH caused by the addition or loss of alkali or acid.

Depending on its physiochemical features, every buffer has one or more pH (negative logarithm of hydrogen ion concentration) values where its ability to keep pH stable is maximal. These values are defined as Ka or semi equivalence points, i.e. the pH values where the buffer dissolved in solution is half in its associated form (AH) and half in its dissociated form (A-).

Several studies tried to determine the normal values of both concentration and Ka of ATOT. However, they did not lead to univocal results. Moreover, many of these values come from studies of veterinary medicine or are the result of theoretical estimates on human plasma.

Staempfli and Constable performed a single experimental study on human plasma in 2003. These authors, however, analyzed only isolated plasma, neglecting whole blood, and computed ATOT and Ka values of healthy volunteers, while Ka and ATOT values for critically ill patients with sepsis are still unknown.

Primary aim of the present study is to quantify the acidic dissociation constant (Ka) of isolated plasma of critically ill patients with sepsis, and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that plasma of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).

Secondary aim is to quantify the Ka of whole blood of critically ill patients with sepsis and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that blood of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).

Other aims of the study are:

  • quantify the Ka of plasma and whole blood of non-septic patients admitted to the ICU and compare these results with the values of septic patients and healthy volunteers.
  • define the normal concentration of weak non-carbonic acids (ATOT) in plasma of septic patients and compare it with data obtained in healthy volunteers and non-septic patients.

Finally, possible structural alteration of plasma proteins will be evaluated:

  • Identification of differentially modified proteoforms of serum albumin and major plasma proteins by two-dimensional electrophoresis;
  • High Performance Liquid Chromatography (HPLC) to identify different Redox-forms of albumin
  • Spectrophotometric evaluation of modifications of ligand binding properties of serum albumin.
Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Determination of Ka of Isolated Plasma and Whole Blood of Critically Ill Patients With Sepsis, Non-septic Patients and Healthy Volunteers: an International, In-vitro Acid-base Study.
Actual Study Start Date : June 3, 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021
Arms and Interventions
Group/Cohort Intervention/treatment
Septic patients
Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

Diagnostic Test: Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.

Healthy controls
Age and sex matched healthy volunteers.
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

Diagnostic Test: Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.

Non septic patients
Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

Diagnostic Test: Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.

Outcome Measures
Primary Outcome Measures :
  1. Effective dissociation constant of plasma weak acids (Ka) [dimensionless] [ Time Frame: 1 day ]
    Difference in plasma Ka between study groups.


Secondary Outcome Measures :
  1. Effective dissociation constant of whole blood weak acids (Ka) [dimensionless] [ Time Frame: 1 day ]
    Difference in whole blood Ka between study groups.

  2. Total concentration of plasma non-volatile buffers (Atot) [mmol/L] [ Time Frame: 1 day ]
    Difference in plasma Atot between study groups.

  3. Total concentration of whole blood non-volatile buffers (Atot) [mmol/L] [ Time Frame: 1 day ]
    Difference in whole blood Atot between study groups.

  4. Non-carbonic buffer power of whole blood due to electrolyte shifts [milliequivalents/L] [ Time Frame: 1 day ]
    Difference in Non-carbonic buffer power of whole blood due to electrolyte shifts between study groups.

  5. Non-carbonic buffer power of isolated plasma due to electrolyte shifts [milliequivalents/L] [ Time Frame: 1 day ]
    Difference in Non-carbonic buffer power of isolated plasma due to electrolyte shifts between study groups.

  6. Oxidized albumin [%] [ Time Frame: 1 day ]
    Difference in the percentage in oxidized albumin between groups.

  7. Characterization of altered ligand binding properties [ Time Frame: 1 day ]
    HSA will be fractionated and dissociation constants for warfarin-SA and diazepam-SA complexes will be obtained spectrophotometrically to evaluate modifications in its ligand binding properties

  8. Identification of differentially modified proteoforms of human serum albumin (HSA) and major plasma proteins. [ Time Frame: 1 day ]
    Samples will be analyzed by two-dimensional electrophoresis.8 After fluorescent staining and image acquisition, proteoform patterns corresponding to HSA and other major plasma proteins will be aligned and compared


Biospecimen Retention:   Samples Without DNA
Plasma samples in ethylenediaminetetraacetic acid for subsequent biomolecular analysis

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
  1. Patients with sepsis or septic shock admitted to the ICU
  2. Healthy volunteers recruited from ICU staff members and relatives
  3. Non-septic patients admitted to the ICU after elective surgery
Criteria

Group 1: Septic patients

Inclusion Criteria for Group 1:

  • Diagnosis of Sepsis
  • Age > 18 years
  • Informed or deferred informed consent

Exclusion Criteria for Group 1:

  • Pregnancy
  • Bilirubin > 4 mg/dL
  • Minor or major thalassemia
  • Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during the 24 hours prior to enrollment

Group 2: Healthy volunteers

Inclusion criteria for Group 2:

  • informed consent
  • Age > 18 years

Exclusion criteria for Group 2:

• Pregnancy

Group 3: Non-septic patients

Inclusion criteria for Group 3:

  • Informed consent
  • Age >18 years
  • Planned ICU admission after elective surgery

Exclusion criteria for Group 3:

  • Diagnosis of sepsis
  • Pregnancy
  • Bilirubin >4 mg/dL
  • Liver cirrhosis
  • Onco-hematological diseases
  • Minor or major thalassemia
  • Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during the 24 hours prior to enrollment
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Thomas Langer, MD 0255033232 thomas.langer@unimi.it

Locations
Layout table for location information
Czechia
Third faculty of Medicine, Charles University of Prague Recruiting
Prague, Czechia
Contact: Frantisek Duska, MD       fduska@yahoo.it   
Principal Investigator: Frantisek Duska, MD         
Sub-Investigator: Martin Krbec, MD         
Sub-Investigator: Petr Waldauf, MD         
Sub-Investigator: Tomas Urban, MD         
Italy
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Recruiting
Milan, Italy, 20122
Contact: Thomas Langer, MD    025503 ext 3232    Thomas.Langer@unimi.it   
Principal Investigator: Thomas Langer, MD         
Sub-Investigator: Serena Brusatori, MD         
Sub-Investigator: Annalisa Mauro, MD         
Sub-Investigator: Paolo Brambilla, MD         
Sponsors and Collaborators
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Charles University, Czech Republic
Investigators
Layout table for investigator information
Principal Investigator: Thomas Langer, MD Fondazione IRCCS Ca' Granda Hospital, Milano, Italy
Study Chair: Antonio M Pesenti, MD Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Principal Investigator: Frantisek Duska, MD Third faculty of Medicine, Charles University, Prague
Study Chair: Giacomo Grasselli, MD Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study Chair: Paul Elbers, MD Amsterdam UMC, Department of Intensive Care Medicine
Tracking Information
First Submitted Date May 27, 2019
First Posted Date May 29, 2019
Last Update Posted Date June 4, 2019
Actual Study Start Date June 3, 2019
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 27, 2019)
Effective dissociation constant of plasma weak acids (Ka) [dimensionless] [ Time Frame: 1 day ]
Difference in plasma Ka between study groups.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: May 27, 2019)
  • Effective dissociation constant of whole blood weak acids (Ka) [dimensionless] [ Time Frame: 1 day ]
    Difference in whole blood Ka between study groups.
  • Total concentration of plasma non-volatile buffers (Atot) [mmol/L] [ Time Frame: 1 day ]
    Difference in plasma Atot between study groups.
  • Total concentration of whole blood non-volatile buffers (Atot) [mmol/L] [ Time Frame: 1 day ]
    Difference in whole blood Atot between study groups.
  • Non-carbonic buffer power of whole blood due to electrolyte shifts [milliequivalents/L] [ Time Frame: 1 day ]
    Difference in Non-carbonic buffer power of whole blood due to electrolyte shifts between study groups.
  • Non-carbonic buffer power of isolated plasma due to electrolyte shifts [milliequivalents/L] [ Time Frame: 1 day ]
    Difference in Non-carbonic buffer power of isolated plasma due to electrolyte shifts between study groups.
  • Oxidized albumin [%] [ Time Frame: 1 day ]
    Difference in the percentage in oxidized albumin between groups.
  • Characterization of altered ligand binding properties [ Time Frame: 1 day ]
    HSA will be fractionated and dissociation constants for warfarin-SA and diazepam-SA complexes will be obtained spectrophotometrically to evaluate modifications in its ligand binding properties
  • Identification of differentially modified proteoforms of human serum albumin (HSA) and major plasma proteins. [ Time Frame: 1 day ]
    Samples will be analyzed by two-dimensional electrophoresis.8 After fluorescent staining and image acquisition, proteoform patterns corresponding to HSA and other major plasma proteins will be aligned and compared
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients
Official Title Determination of Ka of Isolated Plasma and Whole Blood of Critically Ill Patients With Sepsis, Non-septic Patients and Healthy Volunteers: an International, In-vitro Acid-base Study.
Brief Summary Alterations of acid-base equilibrium are very common in critically ill patients and understanding their pathophysiology can be important to improve clinical treatment.
Detailed Description

Acid-base equilibrium has been object of study for more than 100 years in medicine because of its relevance in patients' management and in determining their prognosis, especially in the ICU.

A concept closely related to acid-base equilibrium is that of "buffer", term used to define any substance able to limit the changes in pH caused by the addition or loss of alkali or acid.

Depending on its physiochemical features, every buffer has one or more pH (negative logarithm of hydrogen ion concentration) values where its ability to keep pH stable is maximal. These values are defined as Ka or semi equivalence points, i.e. the pH values where the buffer dissolved in solution is half in its associated form (AH) and half in its dissociated form (A-).

Several studies tried to determine the normal values of both concentration and Ka of ATOT. However, they did not lead to univocal results. Moreover, many of these values come from studies of veterinary medicine or are the result of theoretical estimates on human plasma.

Staempfli and Constable performed a single experimental study on human plasma in 2003. These authors, however, analyzed only isolated plasma, neglecting whole blood, and computed ATOT and Ka values of healthy volunteers, while Ka and ATOT values for critically ill patients with sepsis are still unknown.

Primary aim of the present study is to quantify the acidic dissociation constant (Ka) of isolated plasma of critically ill patients with sepsis, and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that plasma of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).

Secondary aim is to quantify the Ka of whole blood of critically ill patients with sepsis and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that blood of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).

Other aims of the study are:

  • quantify the Ka of plasma and whole blood of non-septic patients admitted to the ICU and compare these results with the values of septic patients and healthy volunteers.
  • define the normal concentration of weak non-carbonic acids (ATOT) in plasma of septic patients and compare it with data obtained in healthy volunteers and non-septic patients.

Finally, possible structural alteration of plasma proteins will be evaluated:

  • Identification of differentially modified proteoforms of serum albumin and major plasma proteins by two-dimensional electrophoresis;
  • High Performance Liquid Chromatography (HPLC) to identify different Redox-forms of albumin
  • Spectrophotometric evaluation of modifications of ligand binding properties of serum albumin.
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Plasma samples in ethylenediaminetetraacetic acid for subsequent biomolecular analysis
Sampling Method Non-Probability Sample
Study Population
  1. Patients with sepsis or septic shock admitted to the ICU
  2. Healthy volunteers recruited from ICU staff members and relatives
  3. Non-septic patients admitted to the ICU after elective surgery
Condition
  • Sepsis
  • Septic Shock
  • Critical Illness
  • Respiratory Acidosis
  • Respiratory Alkalosis
  • Acid-Base Imbalance
Intervention
  • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
    Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
  • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
    Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
  • Diagnostic Test: Biomolecular analysis of plasma proteins.
    Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Study Groups/Cohorts
  • Septic patients
    Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
    Interventions:
    • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
    • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
    • Diagnostic Test: Biomolecular analysis of plasma proteins.
  • Healthy controls
    Age and sex matched healthy volunteers.
    Interventions:
    • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
    • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
    • Diagnostic Test: Biomolecular analysis of plasma proteins.
  • Non septic patients
    Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
    Interventions:
    • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
    • Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
    • Diagnostic Test: Biomolecular analysis of plasma proteins.
Publications *
  • Henderson LJ. THE REGULATION OF NEUTRALITY IN THE ANIMAL BODY. Science. 1913 Mar 14;37(950):389-95.
  • Lee SW, Hong YS, Park DW, Choi SH, Moon SW, Park JS, Kim JY, Baek KJ. Lactic acidosis not hyperlactatemia as a predictor of in hospital mortality in septic emergency patients. Emerg Med J. 2008 Oct;25(10):659-65. doi: 10.1136/emj.2007.055558.
  • Fencl V, Leith DE. Stewart's quantitative acid-base chemistry: applications in biology and medicine. Respir Physiol. 1993 Jan;91(1):1-16. Review.
  • LEEUWEN AM. NET CATION EQUIVALENCY ('BASE BINDING POWER') OF THE PLASMA PROTEINS. Acta Med Scand. 1964;176:SUPPL 422: 1+.
  • Figge J, Mydosh T, Fencl V. Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med. 1992 Nov;120(5):713-9.
  • Stampfli HR, Misiaszek S, Lumsden JH, Carlson GP, Heigenhauser GJ. Weak acid-concentration Atot and dissociation constant Ka of plasma proteins in racehorses. Equine Vet J Suppl. 1999 Jul;(30):438-42.
  • Staempfli HR, Constable PD. Experimental determination of net protein charge and A(tot) and K(a) of nonvolatile buffers in human plasma. J Appl Physiol (1985). 2003 Aug;95(2):620-30. Epub 2003 Mar 28.
  • Langer T, Scotti E, Carlesso E, Protti A, Zani L, Chierichetti M, Caironi P, Gattinoni L. Electrolyte shifts across the artificial lung in patients on extracorporeal membrane oxygenation: interdependence between partial pressure of carbon dioxide and strong ion difference. J Crit Care. 2015 Feb;30(1):2-6. doi: 10.1016/j.jcrc.2014.09.013. Epub 2014 Sep 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: May 27, 2019)
90
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 2021
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Group 1: Septic patients

Inclusion Criteria for Group 1:

  • Diagnosis of Sepsis
  • Age > 18 years
  • Informed or deferred informed consent

Exclusion Criteria for Group 1:

  • Pregnancy
  • Bilirubin > 4 mg/dL
  • Minor or major thalassemia
  • Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during the 24 hours prior to enrollment

Group 2: Healthy volunteers

Inclusion criteria for Group 2:

  • informed consent
  • Age > 18 years

Exclusion criteria for Group 2:

• Pregnancy

Group 3: Non-septic patients

Inclusion criteria for Group 3:

  • Informed consent
  • Age >18 years
  • Planned ICU admission after elective surgery

Exclusion criteria for Group 3:

  • Diagnosis of sepsis
  • Pregnancy
  • Bilirubin >4 mg/dL
  • Liver cirrhosis
  • Onco-hematological diseases
  • Minor or major thalassemia
  • Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during the 24 hours prior to enrollment
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Czechia,   Italy
Removed Location Countries  
 
Administrative Information
NCT Number NCT03966664
Other Study ID Numbers ENTERPRISE
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborators Charles University, Czech Republic
Investigators
Principal Investigator: Thomas Langer, MD Fondazione IRCCS Ca' Granda Hospital, Milano, Italy
Study Chair: Antonio M Pesenti, MD Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Principal Investigator: Frantisek Duska, MD Third faculty of Medicine, Charles University, Prague
Study Chair: Giacomo Grasselli, MD Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study Chair: Paul Elbers, MD Amsterdam UMC, Department of Intensive Care Medicine
PRS Account Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Verification Date June 2019